Latest Revenue Guidance News

Gentrack Group trims its FY26 revenue outlook amid strategic investments and signals a $20 million on-market share buyback post-H1 results.

Ava Risk Group posted a $6.1 million Q3 sales intake and secured a $7 million strategic investment to fuel US expansion, while geopolitical tensions delay some Middle East orders.

Alcidion Group delivered positive cashflow and strong new sales in Q3 FY26, with contract expansions in the UK and Australia. The company remains on track for a significant Electronic Patient Record contract signing in May.

Etherstack has smashed its first half revenue record for FY26 with strong government contract deliveries, prompting an upward revision of full-year revenue guidance to as much as US$18.9 million.

TruScreen Group has met its FY2026 revenue guidance with a 41% jump in product sales, while investing heavily in new markets and pursuing a major UNITAID funding bid that could reshape its medium-term outlook.

FINEOS Corporation Holdings PLC reported its strongest quarterly cash inflow ever alongside key contract wins in Australia and North America, maintaining its FY26 revenue guidance and advancing AI integration in its insurance software platform.

Pureprofile delivered a robust Q3 FY26 with 17% revenue growth and a 67% spike in EBITDA, driven by strong international demand and a doubling of platform revenue. The company reaffirmed its FY26 guidance amid ongoing macroeconomic caution.

Great Divide Mining has transitioned its Challenger Gold Mine in NSW from commissioning to commercial production, targeting a gold concentrate grade of 30 grams per tonne from historic tailings with minimal capital expenditure.

SciDev Ltd trims FY26 revenue guidance to $82-$87 million from $100-$110 million due to intensified competition in Energy Services and weather-related delays at Rum Jungle, while maintaining positive EBITDA and a confident FY27 outlook.

Qantas has sharply revised its FY26 outlook as jet fuel prices soar, doubling its international unit revenue growth forecast while trimming domestic capacity and deferring its share buyback.

Atomos Limited has obtained a new $10 million finance facility from Commonwealth Bank of Australia to support strategic growth initiatives and product development, while also reducing the cost of its existing loan. The company reconfirms its FY26 revenue and EBITDA guidance despite ongoing global uncertainties.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.